8-K: Cytokinetics Announces Positive Phase 3 Trial Results for Aficamten in Hypertrophic Cardiomyopathy

Cytokinetics' aficamten demonstrated significant improvements in exercise capacity and symptoms for patients with obstructive hypertrophic cardiomyopathy in the SEQUOIA-HCM trial.

Summary

• Cytokinetics announced primary results from the SEQUOIA-HCM trial, a Phase 3 study of aficamten for obstructive hypertrophic cardiomyopathy (HCM).
• The trial enrolled 282 patients with symptomatic obstructive HCM, showing well-matched baseline characteristics between treatment groups.
• Aficamten significantly improved exercise capacity, increasing peak oxygen uptake (pVO2) by 1.8 ml/kg/min compared to placebo's 0.0 ml/kg/min, a statistically significant difference of 1.74 mL/kg/min.
• The treatment effect was consistent across all prespecified subgroups, including age, sex, and background beta-blocker therapy.
• Statistically significant improvements were observed in all 10 prespecified secondary endpoints, with functional and symptomatic improvements occurring within two weeks of initiating treatment.
• Aficamten significantly reduced post-Valsalva left ventricular outflow tract gradient (LVOT-G) by 50 mmHg compared to placebo.
• Patients on aficamten showed a 7-point improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and 34% experienced a 1 class improvement in New York Heart Association (NYHA) Functional Class.
• Aficamten reduced the proportion of patients eligible for septal reduction therapy (SRT), with patients spending 78 fewer days eligible for SRT compared to placebo.
• Treatment with aficamten reduced NT-proBNP, a biomarker of cardiac wall stress, by 80% relative to placebo.
• A responder analysis showed that 42% of patients on aficamten achieved a composite responder endpoint compared to 14% on placebo, a placebo-corrected difference of 28.7%.
• Aficamten was well-tolerated, with a similar adverse event profile to placebo, and no treatment interruptions due to low LVEF.
• Additional analyses showed that aficamten dosing was predictable, with most patients achieving one of the two highest doses (15 mg or 20 mg).
• A novel integrated exercise performance metric (CPET Z-score) was improved by a placebo-adjusted difference of 0.35.
• Improvements in pVO2 were highly correlated with improvements in other clinical measures, including KCCQ-CSS, NYHA Functional Class, and LVOT-G.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a Phase 3 trial, with significant improvements across multiple endpoints and a good safety profile. This strongly suggests a positive outlook for the drug's approval and commercial potential.

Positives

• Aficamten demonstrated statistically significant and clinically meaningful improvements in exercise capacity and symptoms for patients with obstructive HCM.
• The treatment effect was consistent across all prespecified subgroups.
• Aficamten was well-tolerated with an adverse event profile comparable to placebo.
• There were no treatment interruptions due to low LVEF.
• The dosing of aficamten was predictable and stable.
• Improvements in exercise performance were strongly correlated with other measures of clinical improvement.

Negatives

• A small percentage of patients (3.5%) on aficamten experienced a core echocardiographic left ventricular ejection fraction (LVEF) of less than 50%, compared to 0.7% on placebo.
• One patient on aficamten had LVEF <40% following a COVID-19 infection, although treatment was not interrupted.

Risks

• The long-term effects of aficamten on cardiac structure and function are still being assessed.
• Regulatory approval is not guaranteed and may require specific labeling or post-marketing obligations.
• The company's future performance is subject to various risks and uncertainties outlined in their SEC filings.

Future Outlook

Cytokinetics is preparing for regulatory submissions for aficamten following the positive results from the SEQUOIA-HCM trial. Aficamten is also being evaluated in other Phase 3 trials for different types of HCM and in a pediatric population.

Management Comments

• The primary results from SEQUOIA-HCM were presented by Martin Maron, M.D., Principal Investigator of SEQUOIA-HCM.
• Additional results were presented by Caroline Coats, M.D., Ph.D., and Gregory Lewis, M.D.

Industry Context

These results position aficamten as a potential next-in-class treatment for obstructive HCM, a significant unmet medical need. The positive data could impact the treatment landscape for this condition, potentially offering a new option for patients who currently have limited choices.

Comparison to Industry Standards

• Current treatments for obstructive HCM include beta-blockers, calcium channel blockers, and disopyramide, which often provide limited symptomatic relief.
• Septal reduction therapy (SRT) is an invasive procedure used for severe cases, but aficamten reduced the need for this therapy.
• The improvements in pVO2 and other clinical measures with aficamten appear to be more substantial than those typically seen with existing therapies.
• Comparable companies developing treatments for HCM include Bristol Myers Squibb with mavacamten, which has shown similar improvements in exercise capacity and symptoms.
• The results from SEQUOIA-HCM are comparable to the EXPLORER-HCM trial for mavacamten, but further head-to-head trials would be needed to determine which drug is superior.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with obstructive HCM may benefit from a new treatment option.
• Healthcare providers may have a new tool for managing this condition.
• Employees of Cytokinetics may be positively impacted by the company's progress.

Next Steps

• Cytokinetics is preparing for regulatory submissions for aficamten.
• The company will continue to evaluate aficamten in other ongoing Phase 3 trials.

Key Dates

Keywords

aficamten, hypertrophic cardiomyopathy, HCM, obstructive HCM, cardiac myosin inhibitor, SEQUOIA-HCM, exercise capacity, peak oxygen uptake, pVO2, LVOT-G, KCCQ-CSS, NYHA Functional Class, NT-proBNP, cardiopulmonary exercise testing, CPET, LVEF